search icon
      blog search icon

      SELB Stock Price History and Quote Analysis: Insights for Investors

      Selecta Biosciences, Inc.

      (NASDAQ:SELB)

      $0.88

      -0.08 (-8.04%)

      Open: 2:08 PM

      SELB Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      SELB Stock Price Today

      Selecta Biosciences, Inc. (SELB) stock declined over -96.69% intraday to trade at $0.8812 a share on NASDAQ. The stock opened with a loss of -96.63% at $0.89 and touched an intraday high of $0.94, falling -96.65% against the last close of $26.34. The Selecta Biosciences, Inc. in stock market went to a low of $0.81 during the session.

      SELB Stock Snapshot

      $26.34

      Prev. Close

      470.45 Million

      Market Cap

      $0.81

      Day Low

      $0.89

      Open

      N/A

      Number of Shares

      $0.94

      Day High

      N/A

      P/E ratio

      -56.02

      EPS (TTM)

      0.73

      Cash Flow per Share

      N/A

      Free Float in %

      0.43

      Book Value

      2.8M

      Volume

      SELB Stock Price History Chart

      DateOpenHighLowCloseVolume

      Contact Details

      65 Grove Street
      Watertown, MA 02472
      US

      Website:https://selectabio.com

      Contact #:617 923 1400

      Company Information

      EmployeesN/A

      BetaN/A

      Sales or Revenue$48.69 Million

      5Y Sales Change230.86%

      Fiscal Year EndsDec. 2022

      SectorHealthcare

      IndustryBiotechnology

      About Company

      Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

      Peers

      Frequently Asked Questions

      icon

      What is the current Selecta Biosciences, Inc. (SELB) stock price?

      Selecta Biosciences, Inc. (NASDAQ: SELB) stock price is $0.88 in the last trading session. During the trading session, SELB stock reached the peak price of $0.94 while $0.81 was the lowest point it dropped to. The percentage change in SELB stock occurred in the recent session was -96.69% while the dollar amount for the price change in SELB stock was -$25.77.

      icon

      SELB's industry and sector of operation?

      The NASDAQ listed SELB is part of Biotechnology industry that operates in the broader Healthcare sector. Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

      icon

      Who are the executives of SELB?

      Dr. Carsten Brunn Ph.D.
      Chief Executive Officer, Pres & Director
      Ms. Ann K. Donohue C.P.A.
      Vice President of Fin. & Controller
      Dr. Carsten Brunn Ph.D.
      CEO, Pres & Director
      Mr. Matthew Bartholomae J.D.
      Gen. Counsel & Sec.

      icon

      How SELB did perform over past 52-week?

      SELB's closing price is 0.65% higher than its 52-week low of $0.785 where as its distance from 52-week high of $1.99 is -0.61%.

      icon

      How many employees does SELB have?

      Number of SELB employees currently stands at N/A. SELB operates from 65 Grove Street, Watertown, MA 02472, US.

      icon

      Link for SELB official website?

      Official Website of SELB is: https://selectabio.com

      icon

      How do I contact SELB?

      SELB could be contacted at phone #617 923 1400 and can also be accessed through its website. SELB operates from 65 Grove Street, Watertown, MA 02472, US.

      icon

      How many shares of SELB are traded daily?

      SELB stock volume for the day was 2763021.00 shares. The average number of SELB shares traded daily for last 3 months was 69.44 Thousands.

      icon

      What is the market cap of SELB currently?

      The market value of SELB currently stands at $470.45 Million with its latest stock price at $0.88 and N/A of its shares outstanding.